SOPHIA GENETICS SA (SOPH) Forecast, Price Target & Analyst Ratings
NASDAQ:SOPH • CH1125843347
4.49 USD
+0.03 (+0.67%)
At close: Mar 10, 2026
4.49 USD
0 (0%)
After Hours: 3/10/2026, 8:00:03 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for SOPHIA GENETICS SA (SOPH).
Forecast Snapshot
Consensus Price Target
$7.48
+ 66.59% Upside
Next Earnings Forecast
Release DateMay 4, 2026
PeriodQ1 / 2026
EPS Estimate-$0.25
Revenue Estimate20.808M
ChartMill Buy Consensus
86.00%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$7.48
Upside
+ 66.59%
From current price of $4.49 to mean target of $7.48, Based on 10 analyst forecasts
Low
$6.06
Median
$7.14
High
$9.45
Price Target Revisions
1 Month
0.00%
3 Months
0.00%
Price Target Summary
10 Wall Street analysts provided a forecast for the next 12 months for SOPH. The average price target is 7.48 USD. This implies a price increase of 66.59% is expected in the next year compared to the current price of 4.49.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
86.00%
SOPH was analyzed by 10 analysts. The buy percentage consensus is at 86. So analysts seem to be very confident about SOPH.
In the previous month the buy percentage consensus was at a similar level.
SOPH was analyzed by 10 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-01-26 | Guggenheim | Maintains | Buy -> Buy |
| 2025-11-10 | BTIG | Maintains | Buy -> Buy |
| 2024-12-18 | Craig-Hallum | Initiate | Buy |
| 2024-08-07 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-06-27 | Guggenheim | Initiate | Buy |
| 2024-03-06 | BTIG | Maintains | Buy -> Buy |
| 2024-03-06 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-01-12 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2023-11-29 | RBC Capital | Initiate | Outperform |
| 2023-05-10 | Credit Suisse | Maintains | Neutral |
| 2023-05-10 | Morgan Stanley | Maintains | Overweight |
| 2023-03-08 | Morgan Stanley | Maintains | Overweight |
| 2023-01-03 | BTIG | Initiate | Buy |
| 2022-11-23 | Credit Suisse | Initiate | Neutral |
| 2022-11-09 | Morgan Stanley | Maintains | Overweight |
| 2022-08-10 | Morgan Stanley | Maintains | Overweight |
| 2022-05-11 | Morgan Stanley | Maintains | Overweight |
| 2022-02-15 | Morgan Stanley | Maintains | Overweight |
| 2021-08-17 | Cowen & Co. | Initiate | Outperform |
| 2021-08-17 | JP Morgan | Initiate | Overweight |
| 2021-08-17 | Credit Suisse | Initiate | Outperform |
| 2021-08-17 | Morgan Stanley | Initiate | Overweight |
Next Earnings Forecast Details
Next Earnings Details
Release DateMay 4, 2026
PeriodQ1 / 2026
EPS Estimate-$0.25
Revenue Estimate20.808M
Revenue Q2Q17.04%
EPS Q2Q4.87%
Number of Analysts6
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
-0.20%
EPS (1 Month)
0.00%
EPS (3 Months)
-3.26%
Next Earnings Summary
SOPH is expected to report earnings on 5/4/2026. The consensus EPS estimate for the next earnings is -0.25 USD and the consensus revenue estimate is 20.81M USD.
The next earnings revenue estimate has been revised downward by 0.2% in the past 3 months.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | ||
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 62.371M 31.14% | 65.173M 4.49% | 77.271M 18.56% | 89.76M 16.16% | 105.52M 17.56% | 132.04M 25.13% | 184.31M 39.59% | 238.99M 29.67% | |
| EBITDA YoY % growth | -66.49M 19.16% | -57.972M 12.81% | -58.052M -0.14% | -37.692M 35.07% | -26.806M 28.88% | -8.823M 67.09% | 24.786M 380.92% | 61.608M 148.56% | |
| EBIT YoY % growth | -74.826M 14.80% | -66.568M 11.04% | -67.581M -1.52% | -61.967M 8.31% | -52.229M 15.72% | -32.283M 38.19% | -5.712M 82.31% | 29.478M 616.07% | |
| Operating Margin | -119.97% | -102.14% | -87.46% | -69.04% | -49.50% | -24.45% | -3.10% | 12.33% | |
| EPS YoY % growth | -1.22 -4.27% | -0.95 22.13% | -1.12 -17.89% | -0.91 18.49% | -0.75 17.60% | N/A | N/A | N/A |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.25 4.87% | -0.25 25.05% | -0.23 18.95% | -0.20 21.12% | -0.21 13.40% | -0.18 25.77% | -0.15 32.58% | -0.12 37.93% |
| Revenue Q2Q % growth | 20.808M 17.04% | 21.522M 17.46% | 22.925M 17.79% | 24.582M 13.24% | 22.746M 9.31% | 24.888M 15.64% | 26.52M 15.68% | 28.866M 17.43% |
| EBITDA Q2Q % growth | -9.914M 27.84% | -9.177M 33.62% | -9.05M 6.90% | -5.952M 11.33% | -9.404M 5.14% | -7.14M 22.19% | -5.202M 42.52% | -3.06M 48.59% |
| EBIT Q2Q % growth | -16.391M -2.22% | -16.729M 9.53% | -15.345M 8.73% | -3.818M 76.49% | -16.443M -0.32% | -14.295M 14.55% | -12.233M 20.28% | -10.189M -166.84% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
19.58%
Revenue Next 5 Year
25.35%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
23.30%
EBIT Next 5 Year
23.54%
SOPHIA GENETICS SA / SOPH Forecast FAQ
Can you provide the average price target for SOPHIA GENETICS SA stock?
10 analysts have analysed SOPH and the average price target is 7.48 USD. This implies a price increase of 66.59% is expected in the next year compared to the current price of 4.49.
Can you provide the upcoming earnings date for SOPHIA GENETICS SA?
SOPHIA GENETICS SA (SOPH) will report earnings on 2026-05-04.
What are the consensus estimates for SOPHIA GENETICS SA (SOPH) next earnings?
The consensus EPS estimate for the next earnings of SOPHIA GENETICS SA (SOPH) is -0.25 USD and the consensus revenue estimate is 20.81M USD.
How many analysts have analysed SOPHIA GENETICS SA (SOPH)?
The number of analysts covering SOPHIA GENETICS SA (SOPH) is 10.